To assess cognitive changes, the researchers compared the lecanemab-treated group in the open-label extension against a matched cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Continued lecanemab treatment linked to significant disease-modifying effects. No new safety signals were observed during the open-label extension phase. In an open-label extension of the CLARITY ...

Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline ...

(RTTNews) - Responding to Media reports, Eisai Co., Ltd. clarified that its investigational Alzheimer's disease drug lecanemab is not associated with two deaths involving brain bleeding that ...

For researchers in the field, the arrival of these two therapies called Lecanemab and Donanemab is testament to decades of advancements in the field of Alzheimer's research because for the first ...